Outcomes for patients with myeloid blast phase chronic myeloid leukemia (CML-MBP) are dismal, and no preferred chemotherapy regimen has been identified. This evidence concerns the gene MBP and chronic myelogenous leukemia, BCR-ABL1 positive.